This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SLNO Soleno Therapeutics (SLNO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsInsider TradesNews and TrendsOwnership About Soleno Therapeutics Stock (NASDAQ:SLNO) Get Soleno Therapeutics alerts:Sign Up Key Stats Today's Range$53.01▼$53.0150-Day Range$30.05▼$53.0152-Week Range$29.43▼$90.32VolumeN/AAverage Volume1.75 million shsMarket Capitalization$2.76 billionP/E Ratio29.95Dividend YieldN/APrice Target$65.57Consensus RatingReduce Company Overview Soleno Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations. The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges. Soleno has completed multiple clinical trials of DCCR in adults and adolescents with PWS, evaluating its effects on hyperphagia, body composition and metabolic parameters. In addition to PWS, Soleno is advancing a proprietary formulation called SEZ982 for the treatment of phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare inherited condition that leads to multi-systemic impairment due to deficient protein glycosylation. Since its inception, Soleno has built a development pipeline rooted in rigorous translational research and active engagement with patient advocacy communities. The company works closely with academic collaborators and clinical centers of excellence across North America and Europe to design studies that address the full spectrum of disease manifestations. Soleno’s team combines expertise in drug formulation, clinical trial execution and regulatory strategy to expedite the path from laboratory discovery to potential market approval. Led by an experienced management team with deep backgrounds in biotech development and commercialization, Soleno continues to expand its scientific capabilities and prepare for potential regulatory submissions. The company maintains strategic partnerships and seeks to broaden its portfolio by identifying additional rare disease opportunities where small‐molecule therapies can deliver meaningful clinical outcomes. Through a patient-focused model, Soleno aims to bring new treatment options to communities with high unmet medical needs.AI Generated. May Contain Errors. Read More Soleno Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreSLNO MarketRank™: 2.58006405124 of 5 starsSoleno Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 486th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingReduce Consensus RatingSoleno Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.91, and is based on no strong buy ratings, 1 buy rating, 8 hold ratings, and 2 sell ratings.Upside PotentialSoleno Therapeutics has a consensus price target of $65.57, representing about 23.7% upside from its current price of $53.01.Amount of Analyst CoverageSoleno Therapeutics has received no research coverage in the past 90 days.Read more about Soleno Therapeutics' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth46.05% Earnings GrowthEarnings for Soleno Therapeutics are expected to grow by 46.05% in the coming year, from $3.67 to $5.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soleno Therapeutics is 29.95, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 36.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Soleno Therapeutics is 29.95, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 225.18.Price to Book Value per Share RatioSoleno Therapeutics has a P/B Ratio of 5.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for SLNO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSoleno Therapeutics does not currently pay a dividend.Dividend GrowthSoleno Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for SLNO on MarketBeat in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Soleno Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.40% of the stock of Soleno Therapeutics is held by insiders.Percentage Held by Institutions97.42% of the stock of Soleno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Soleno Therapeutics' insider trading history. Receive SLNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLNO Stock News HeadlinesKuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law FirmSeptember 2, 2026 | prnewswire.comSLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens BermanMay 11, 2026 | prnewswire.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 21 at 1:00 AM | The Oxford Club (Ad)Soleno Merger With Neurocrine Puts Profitability And Valuation In FocusMay 10, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNOMay 5, 2026 | globenewswire.comSLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class ActionMay 5, 2026 | prnewswire.comDEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersMay 5, 2026 | globenewswire.comSLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law FirmMay 5, 2026 | prnewswire.comSee More Headlines SLNO Stock Analysis - Frequently Asked Questions How were Soleno Therapeutics' earnings last quarter? Soleno Therapeutics, Inc. (NASDAQ:SLNO) released its quarterly earnings results on Wednesday, February, 25th. The company reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.16. The company earned $91.73 million during the quarter, compared to analysts' expectations of $88.55 million. Soleno Therapeutics had a trailing twelve-month return on equity of 22.85% and a net margin of 33.70%. Read the conference call transcript. When did Soleno Therapeutics' stock split? Soleno Therapeutics shares reverse split on Friday, August 26th 2022.The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Soleno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Soleno Therapeutics investors own include Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Palantir Technologies (PLTR), Sorrento Therapeutics (SRNE), Tesla (TSLA) and TherapeuticsMD (TXMD). Company Calendar Last Earnings2/25/2026Today10/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SLNO's financial health is in the Green zone, according to TradeSmith. SLNO has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SLNO CIK1484565 Webwww.soleno.life Phone(650) 213-8444Fax650-213-8383Employees30Year Founded1999Price Target and Rating Average Price Target for Soleno Therapeutics$65.57 High Price Target$107.00 Low Price Target$53.00 Potential Upside/Downside+23.7%Consensus RatingReduce Rating Score (0-4)1.91 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$1.77 Trailing P/E Ratio29.95 Forward P/E Ratio14.44 P/E GrowthN/ANet Income$20.89 million Net Margins33.70% Pretax Margin34.94% Return on Equity22.85% Return on Assets18.25% Debt Debt-to-Equity Ratio0.10 Current Ratio5.62 Quick Ratio5.32 Sales & Book Value Annual Sales$285.01 million Price / Sales9.69 Cash Flow$0.43 per share Price / Cash Flow124.10 Book Value$9.51 per share Price / Book5.57Miscellaneous Outstanding Shares52,120,000Free Float48,784,000Market Cap$2.76 billion OptionableOptionable Beta-2.22 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:SLNO) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | Sponsored3 tickers just showed unusual early patterns. See the Trading Ideas report now.Spot the Signals Before They Become Obvious We track early shifts in volume, structure, and emerging trends...Trading Ideas | SponsoredPalantir Micron and SanDisk surged before anyone noticedPalantir, Micron, and SanDisk show how fast a stock can move from overlooked to impossible to ignore. A new...StockEarnings | SponsoredBeginner’s Guide to GoldInflation, trade wars, and market volatility have many savers rethinking how they protect retirement funds. A ...Goldco Direct, LLC | SponsoredThe Calm Before the Rotation — What’s Quietly Building Now (Stock Wire News)Your Access to Private Market Briefings Begins Here Stock Wire News delivers select early alerts typically ...Stock Wire News | SponsoredFox News: Wall Street Can Seize Your RetirementFox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
